KIEV. August 14. UNN. Coronavirus vaccines being developed in the United States are unlikely to be registered until November. About this reported Reuters with reference to the head of the US National Institutes of Health Francis Collins, writes UNN.
According to him, potential vaccines under the US administration’s Operation Warp Speed program are unlikely to receive regulatory approval before November-December. This is due to the need for large-scale clinical trials. According to Collins, the involvement of about 10,000 volunteers will gather enough information about the safety and effectiveness of drugs for widespread use.
According to President Donald Trump on Tuesday, the United States will produce about 600 million doses of vaccines if approved by experts.
The US government has provided $ 1.2 billion to the British-Swedish pharmaceutical company AstraZeneca, which is developing the vaccine together with scientists from Oxford University (UK). The Washington administration also sent $ 486 million to the American biotechnology company Moderna and $ 456 million to the pharmaceutical company Johnson & Johnson. Merck and Pfizer are also developing a coronavirus vaccine in the United States. According to the White House, the administration has invested a total of $ 12 billion.
At the same time, US President Donald Trump was informed about the vaccine created in Russia against the new coronavirus “Satellite V”. On August 11, Russian President Vladimir Putin announced the registration in Russia of “the world’s first vaccine against coronavirus.”